HomeCompareCOGZF vs SBUX

COGZF vs SBUX: Dividend Comparison 2026

COGZF yields 0.87% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $136.6K in total portfolio value
10 years
COGZF
COGZF
● Live price
0.87%
Share price
$1.50
Annual div
$0.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.9K
Annual income
$91.72
Full COGZF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — COGZF vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCOGZFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, COGZF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
COGZF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

COGZF
Annual income on $10K today (after 15% tax)
$73.70/yr
After 10yr DRIP, annual income (after tax)
$77.96/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, SBUX beats the other by $55,886.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of COGZF + SBUX for your $10,000?

COGZF: 50%SBUX: 50%
100% SBUX50/50100% COGZF
Portfolio after 10yr
$89.2K
Annual income
$32,965.92/yr
Blended yield
36.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

COGZF
No analyst data
Altman Z
12.8
Piotroski
8/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

COGZF buys
0
SBUX buys
0
No recent congressional trades found for COGZF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCOGZFSBUX
Forward yield0.87%2.75%
Annual dividend / share$0.01$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$20.9K$157.5K
Annual income after 10y$91.72$65,840.13
Total dividends collected$894.00$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: COGZF vs SBUX ($10,000, DRIP)

YearCOGZF PortfolioCOGZF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$10,787$86.70$11,107$407.21$320.00SBUX
2$11,629$87.40$12,512$626.87$883.00SBUX
3$12,531$88.07$14,366$978.69$1.8KSBUX
4$13,497$88.69$16,929$1,557.50$3.4KSBUX
5$14,531$89.28$20,658$2,543.80$6.1KSBUX
6$15,638$89.83$26,406$4,302.22$10.8KSBUX
7$16,823$90.35$35,877$7,622.00$19.1KSBUX
8$18,092$90.83$52,741$14,352.64$34.6KSBUX
9$19,449$91.29$85,676$29,243.03$66.2KSBUX
10$20,903$91.72$157,513$65,840.13$136.6KSBUX

COGZF vs SBUX: Complete Analysis 2026

COGZFStock

Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.

Full COGZF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this COGZF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

COGZF vs SCHDCOGZF vs JEPICOGZF vs OCOGZF vs KOCOGZF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.